[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PE20191474A1 - Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer - Google Patents

Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer

Info

Publication number
PE20191474A1
PE20191474A1 PE2019001276A PE2019001276A PE20191474A1 PE 20191474 A1 PE20191474 A1 PE 20191474A1 PE 2019001276 A PE2019001276 A PE 2019001276A PE 2019001276 A PE2019001276 A PE 2019001276A PE 20191474 A1 PE20191474 A1 PE 20191474A1
Authority
PE
Peru
Prior art keywords
compounds
cancer
amino
treatment
triazolopyridine compounds
Prior art date
Application number
PE2019001276A
Other languages
English (en)
Inventor
Maurice Raymond Verschoyle Finlay
Frederick Woolf Goldberg
Attilla Kuan Tsuei Ting
Original Assignee
Astrazeneca Ab
Cancer Research Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Cancer Research Tech Ltd filed Critical Astrazeneca Ab
Publication of PE20191474A1 publication Critical patent/PE20191474A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/502Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La memoria descriptiva se refiere a compuestos de Formula (I) o sales farmaceuticamente aceptables de los mismos, donde R1 es ciclohexilo, tetrahidrofuranilo u oxanilo y R2 es H o metilo. Tambien esta referida a composiciones farmaceuticas y kits que comprenden los compuestos de formula (I). Dichos compuestos son utiles para tratar o prevenir una enfermedad mediada por PC-ADN, incluyendo el cancer
PE2019001276A 2016-12-20 2017-12-19 Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer PE20191474A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662436619P 2016-12-20 2016-12-20
PCT/EP2017/083625 WO2018114999A1 (en) 2016-12-20 2017-12-19 Amino-triazolopyridine compounds and their use in treating cancer

Publications (1)

Publication Number Publication Date
PE20191474A1 true PE20191474A1 (es) 2019-10-16

Family

ID=60937727

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019001276A PE20191474A1 (es) 2016-12-20 2017-12-19 Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer

Country Status (38)

Country Link
US (4) US10407446B2 (es)
EP (1) EP3558997B1 (es)
JP (1) JP6883653B2 (es)
KR (1) KR102220971B1 (es)
CN (1) CN110177791B (es)
AR (1) AR110400A1 (es)
AU (1) AU2017384388B2 (es)
BR (1) BR112019012217B1 (es)
CA (1) CA3046339C (es)
CL (1) CL2019001714A1 (es)
CO (1) CO2019007810A2 (es)
CR (1) CR20190301A (es)
CY (1) CY1124239T1 (es)
DK (1) DK3558997T3 (es)
DO (1) DOP2019000168A (es)
EA (1) EA037745B1 (es)
EC (1) ECSP19044159A (es)
ES (1) ES2867274T3 (es)
HR (1) HRP20210548T1 (es)
HU (1) HUE054548T2 (es)
IL (1) IL267158B (es)
JO (1) JOP20190151B1 (es)
LT (1) LT3558997T (es)
MA (1) MA47079B1 (es)
MX (1) MX2019007189A (es)
MY (1) MY183036A (es)
NI (1) NI201900062A (es)
NZ (1) NZ755222A (es)
PE (1) PE20191474A1 (es)
PH (1) PH12019501350A1 (es)
PL (1) PL3558997T3 (es)
PT (1) PT3558997T (es)
RS (1) RS61701B1 (es)
SI (1) SI3558997T1 (es)
TW (1) TWI776835B (es)
UA (1) UA123032C2 (es)
WO (1) WO2018114999A1 (es)
ZA (1) ZA201904695B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102220971B1 (ko) 2016-12-20 2021-02-25 아스트라제네카 아베 아미노-트리아졸로피리딘 화합물 및 암 치료에서의 이의 용도
TWI820146B (zh) 2018-06-15 2023-11-01 瑞典商阿斯特捷利康公司 嘌呤酮化合物及其在治療癌症中之用途
WO2020186211A1 (en) * 2019-03-13 2020-09-17 The Uab Research Foundation Methods and compositions for treating polyoma virus infection
TW202110849A (zh) * 2019-05-27 2021-03-16 大陸商迪哲(江蘇)醫藥股份有限公司 Dna依賴性蛋白激酶抑制劑
US20210008161A1 (en) 2019-06-17 2021-01-14 Crispr Therapeutics Ag Methods and compositions for improved homology directed repair
IL293211A (en) * 2019-11-22 2022-07-01 Medshine Discovery Inc Pyrimidopyrrole spiro compounds and their derivatives as dna-pk inhibitors
IL293318A (en) * 2019-11-25 2022-07-01 Medshine Discovery Inc Pyrimidoimidazole compounds used as dna-pk inhibitors
CA3163093A1 (en) 2019-11-26 2021-06-03 Primmune Therapeutics, Inc. Tlr7 agonists
CN113121574B (zh) * 2019-12-31 2023-02-17 成都百裕制药股份有限公司 嘌呤衍生物及其在医药上的用途
CN113121573A (zh) * 2019-12-31 2021-07-16 成都百裕制药股份有限公司 嘌呤衍生物及其在医药上的应用
WO2021136462A1 (zh) * 2019-12-31 2021-07-08 成都百裕制药股份有限公司 呋喃衍生物及其在医药上的应用
CN113493471B (zh) * 2020-04-03 2024-06-11 山东轩竹医药科技有限公司 杂芳环类激酶抑制剂
KR20230004697A (ko) * 2020-04-17 2023-01-06 청두 바이위 파머수티컬 씨오., 엘티디 이미다졸리디논 유도체 및 그 의학적 용도
CN113549092B (zh) * 2020-04-23 2022-10-18 山东轩竹医药科技有限公司 三并环类激酶抑制剂
JP2023524666A (ja) 2020-04-28 2023-06-13 インテリア セラピューティクス,インコーポレイテッド インビトロ細胞送達の方法
WO2021260583A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and dna-pk inhibitor
CN116406272A (zh) * 2020-07-20 2023-07-07 首药控股(北京)股份有限公司 Dna-pk选择性抑制剂及其制备方法和用途
US20220040173A1 (en) * 2020-08-04 2022-02-10 Astrazeneca Ab Methods of delaying pain progression and treating prostate cancer
CN114249753A (zh) * 2020-09-22 2022-03-29 山东轩竹医药科技有限公司 三唑并吡啶类激酶抑制剂
JP2023542548A (ja) * 2020-09-24 2023-10-10 オークランド ユニサービシズ リミテッド 新規アミノピリジン及びその癌治療への使用
CN114634522A (zh) * 2020-12-15 2022-06-17 江苏恒瑞医药股份有限公司 嘌呤酮衍生物、其制备方法及其在医药上的应用
AU2021400745A1 (en) 2020-12-17 2023-07-20 Vertex Pharmaceuticals Incorporated Compositions and methods for editing beta-globin for treatment of hemaglobinopathies
CN116685323A (zh) * 2020-12-21 2023-09-01 江苏恒瑞医药股份有限公司 嘌呤酮衍生物、其制备方法及其在医药上的应用
CN114656487B (zh) * 2020-12-22 2023-11-14 江苏恒瑞医药股份有限公司 稠合嘧啶类化合物、其制备方法及其在医药上的应用
WO2022135555A1 (zh) * 2020-12-24 2022-06-30 江苏恒瑞医药股份有限公司 嘌呤酮类化合物、其制备方法及其在医药上的应用
WO2022199547A1 (zh) * 2021-03-22 2022-09-29 成都赜灵生物医药科技有限公司 一种7,9-二氢嘌呤衍生物及其制药用途
CR20230535A (es) 2021-04-17 2024-02-16 Intellia Therapeutics Inc Inhibidores de proteína cinasa dependiente de adn y composiciones y usos de estos
CN117355526A (zh) * 2021-05-19 2024-01-05 再鼎医药(上海)有限公司 杂环取代的嘌呤酮衍生物的盐型及晶型
CN117377676A (zh) * 2021-06-29 2024-01-09 成都百裕制药股份有限公司 嘌呤衍生物的晶型及其药物组合物
WO2023220418A2 (en) * 2022-05-13 2023-11-16 The Board Of Trustees Of The Leland Stanford Junior University Enhancing gene targeting efficiency in human cells with dna-pk inhibitor treatment
WO2024121753A1 (en) 2022-12-06 2024-06-13 Astrazeneca Ab Polq inhibitors

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
ES2194181T3 (es) 1996-02-13 2003-11-16 Astrazeneca Ab Derivados de quinazolina como inhibidores de vegf.
CA2244897C (en) 1996-03-05 2006-04-11 Zeneca Limited 4-anilinoquinazoline derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US6432947B1 (en) 1997-02-19 2002-08-13 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
US7749999B2 (en) 2003-09-11 2010-07-06 Itherx Pharmaceuticals, Inc. Alpha-ketoamides and derivatives thereof
KR20060129023A (ko) 2004-02-23 2006-12-14 다이닛본 스미토모 세이야꾸 가부시끼가이샤 신규한 헤테로환 화합물
AU2006205851A1 (en) 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. 5-membered annelated heterocyclic pyrimidines as kinase inhibitors
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US20090023723A1 (en) 2005-09-21 2009-01-22 Pharmacopeia Drug Discovery, Inc. Purinone derivatives for treating neurodegenerative diseases
BRPI0617241A2 (pt) 2005-10-13 2016-11-08 Glaxo Group Ltd composto ou um sal ou solvato do mesmo, composição farmacêutica, método para tratar uma doença ou condição mediada por atividade syk inadequada em um mamífero, e, uso de um composto ou um sal ou solvato farmaceuticamente aceitável do mesmo
WO2007058990A2 (en) 2005-11-14 2007-05-24 Kemia, Inc. Therapy using cytokine inhibitors
TWI398252B (zh) 2006-05-26 2013-06-11 Novartis Ag 吡咯并嘧啶化合物及其用途
WO2007146712A2 (en) 2006-06-09 2007-12-21 Kemia, Inc. Therapy using cytokine inhibitors
CL2007002866A1 (es) 2006-10-04 2008-07-04 Pharmacopeia Inc Compuestos derivados de 6-sustituidos-2-(bencimidazolil) purina y purinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de enfermedades autoinmunes, enfermedad inflamatoria, enfermedad mediada por m
US7902187B2 (en) 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
CN105693730A (zh) 2006-10-19 2016-06-22 西格诺药品有限公司 杂芳基化合物、其组合物以及它们作为蛋白激酶抑制剂的用途
PT2168966T (pt) 2007-06-15 2017-01-02 Msd Kk Derivado de bicicloanilina
AU2008290330A1 (en) 2007-08-23 2009-02-26 Astrazeneca Ab 2-anilinopurin-8-ones as inhibitors of TTK/Mps1 for the treatment of proliferative disorders
WO2009122180A1 (en) * 2008-04-02 2009-10-08 Medical Research Council Pyrimidine derivatives capable of inhibiting one or more kinases
JP2012197231A (ja) 2009-08-06 2012-10-18 Oncotherapy Science Ltd Ttk阻害作用を有するピリジンおよびピリミジン誘導体
AR079814A1 (es) 2009-12-31 2012-02-22 Otsuka Pharma Co Ltd Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos
US9555033B2 (en) 2010-02-03 2017-01-31 Signal Pharmaceuticals, Llc Identification of LKB1 mutation as a predictive biomarker for sensitivity to TOR kinase inhibitors
MX2012011912A (es) 2010-04-13 2012-11-16 Novartis Ag Combinacion que comprende un inhibidor de cinasa 4 dependiente de ciclina o cinasa dependiente de ciclia (cdk4/6) y un inhibidor de mtor para tratar cancer.
AR086196A1 (es) 2011-04-21 2013-11-27 Origenis Gmbh Derivados de pirazolo[3,4-c]quinolina, inhibidores de quinasa
US9499535B2 (en) 2011-04-21 2016-11-22 Origenis Gmbh Kinase inhibitors
EP2527344A1 (en) * 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
JP6121658B2 (ja) 2011-06-29 2017-04-26 大塚製薬株式会社 治療用化合物、及び関連する使用の方法
WO2013059396A2 (en) 2011-10-19 2013-04-25 Signal Pharmaceuticals, Llc Treatment of cancer with tor kinase inhibitors
KR20200034818A (ko) * 2012-03-15 2020-03-31 시그날 파마소티칼 엘엘씨 Tor 키나제 억제제를 사용한 암의 치료
CN102675897B (zh) 2012-05-18 2015-04-29 陕西师范大学 硫脲/脲芳胺染料及其制备方法和应用
CN103864792B (zh) 2012-12-12 2017-01-18 山东亨利医药科技有限责任公司 作为酪氨酸激酶抑制剂的含氮并环类化合物
CA2902858A1 (en) 2013-02-28 2014-09-04 Signal Pharmaceuticals, Llc Treatment of cancer with tor kinase inhibitors
NO2714752T3 (es) 2014-05-08 2018-04-21
KR102220971B1 (ko) 2016-12-20 2021-02-25 아스트라제네카 아베 아미노-트리아졸로피리딘 화합물 및 암 치료에서의 이의 용도

Also Published As

Publication number Publication date
BR112019012217B1 (pt) 2021-08-10
DOP2019000168A (es) 2019-07-15
MA47079A (fr) 2019-10-30
RS61701B1 (sr) 2021-05-31
AR110400A1 (es) 2019-03-27
AU2017384388B2 (en) 2020-09-17
IL267158B (en) 2020-10-29
TW201837045A (zh) 2018-10-16
CA3046339A1 (en) 2018-06-28
US20200048281A1 (en) 2020-02-13
WO2018114999A1 (en) 2018-06-28
PT3558997T (pt) 2021-04-13
ECSP19044159A (es) 2019-06-30
CR20190301A (es) 2019-09-04
MY183036A (en) 2021-02-08
PL3558997T3 (pl) 2021-07-19
JP2020504107A (ja) 2020-02-06
US20180194782A1 (en) 2018-07-12
KR20190092573A (ko) 2019-08-07
MX2019007189A (es) 2019-10-09
US20220041625A1 (en) 2022-02-10
TWI776835B (zh) 2022-09-11
CO2019007810A2 (es) 2019-10-09
HUE054548T2 (hu) 2021-09-28
US11136340B2 (en) 2021-10-05
NI201900062A (es) 2020-07-22
LT3558997T (lt) 2021-04-26
JOP20190151B1 (ar) 2023-09-17
KR102220971B1 (ko) 2021-02-25
CA3046339C (en) 2022-02-22
IL267158A (en) 2019-08-29
UA123032C2 (uk) 2021-02-03
SI3558997T1 (sl) 2021-07-30
EP3558997A1 (en) 2019-10-30
JP6883653B2 (ja) 2021-06-09
ZA201904695B (en) 2021-05-26
BR112019012217A2 (pt) 2019-11-12
CY1124239T1 (el) 2022-07-22
MA47079B1 (fr) 2021-05-31
EP3558997B1 (en) 2021-01-27
CN110177791A (zh) 2019-08-27
AU2017384388A1 (en) 2019-07-25
US10407446B2 (en) 2019-09-10
EA201991399A1 (ru) 2020-01-22
CN110177791B (zh) 2022-07-12
EA037745B1 (ru) 2021-05-18
PH12019501350A1 (en) 2020-01-20
HRP20210548T1 (hr) 2021-05-14
NZ755222A (en) 2022-07-01
US11746118B2 (en) 2023-09-05
ES2867274T3 (es) 2021-10-20
JOP20190151A1 (ar) 2019-06-20
US20240124492A1 (en) 2024-04-18
CL2019001714A1 (es) 2019-09-06
DK3558997T3 (da) 2021-04-19

Similar Documents

Publication Publication Date Title
PE20191474A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer
NI202000099A (es) Compuestos de purinona y su uso en el tratamiento del cáncer
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CL2017000469A1 (es) Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1
CR20170563A (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso.
CO2018003969A2 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
DOP2018000115A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
AR108461A1 (es) Compuestos imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
CL2019002900A1 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
DOP2016000308A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
DOP2018000197A (es) Compuestos de cinnolin-4-amina y su uso en el tratamiento del cáncer
CL2019002480A1 (es) Derivados de pirazol como inhibidores de bromodominio.
CO2021001925A2 (es) Piridopirimidinas como inhibidores del receptor de histamina h4
CR20170332A (es) Derivados de fumagilol
AR100621A1 (es) COMPUESTO INHIBIDOR DE FOSFOINOSÍTIDO-3-QUINASA d, COMPOSICIÓN FARMACÉUTICA, USO, MÉTODO